Prostate Disease Articles & Analysis: Older
18 news found
Nubeqa is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
Prostatitis is a disease characterized by the presence of inflammation and/or infection localized in the prostate gland. ...
Prostate cancer is the most common type of cancer in men. Every year this diagnosis is made about 900 thousand times, in developed countries the disease affects up to 14% of the entire male population with oncology due to longer life expectancy. We spoke with adult prostate cancer survivors. ...
The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the detection and clinical management of men >45 years of age at risk for prostate cancer. "An estimated 268,490 men will be diagnosed with prostate cancer in 2022 according to the American Cancer Society. miR Scientific's vision is to ...
The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men >45 years of age at risk for prostate cancer. ...
In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions. For more information about Qualigen Therapeutics, Inc., ...
“For decades, GE Healthcare has proudly equipped clinicians with advanced MRI technologies to visualize and diagnose prostate cancer. Now, we are proud to enable access to a new tool to help clinicians treat this disease under precise MRI guidance: Profound’s TULSA-PRO®. This noninvasive MRI-guided therapy technology is customized to each patient ...
Stephen Neidle Session Title: New Chemotherapy Agents Session Date and Time: Wednesday Apr 13, 2022 9:00 AM - 12:30 PM CDT Abstract Number: 4068 Title: “The potent quadruplex-binding compound SOP1812 shows potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo model of metastatic ...
However, for men with larger prostates greater than 50 milliliters, IPSS reduction was 3.5 points greater across all follow-up visits in the Aquablation group compared to the TURP group (p=.0123). ...
In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions. For more information about Qualigen Therapeutics, Inc., ...
” Aquablation therapy combines real-time, multi-dimensional imaging, automated robotics, and heat-free waterjet ablation for targeted, controlled, and immediate removal of prostate tissue. Combining both cystoscopic visualization and ultrasound imaging, surgeons can create a personalized treatment plan tailored to each patient’s anatomy. ...
FDA cleared for in-office use, the Company’s single-sided MRI system with AI based imaging empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo scanner. “Our technology enables safe and effective point of care diagnostic biopsies and treatment of cancers, overcoming limitations of traditional MRIs, and paving ...
In addition to an attractive oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid testing systems for the management of prostate cancer and other diseases and health conditions. Qualigen is managed by a team of seasoned experts in drug and medical device development, ...
The team will collaborate on the development of a best-in-class targeting agent for metastatic prostate cancer, a disease that affects millions of patients worldwide. ...
ByInterX
“TULSA-PRO® is a customizable and incision-free prostate disease treatment system that minimizes the impact on men’s functional abilities and provides the highest quality of life after treatment. ...
The novel applicators are designed to respectively deliver point, linear or planar shockwaves compatible with treating urinary stones, calcified leg arteries, prostate, Chronic Kidney Disease (CKD) and more. Target localization in various patient positions is achieved by motorized and manual applicator’s motion in conjunction with in-line ultrasonic ...
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company focusing on small molecules that bind to pivotal enzyme cancer targets, announced that it received a Small Business Innovation Research (SBIR) grant to develop CTT1700, a unique prodrug targeted at men with prostate cancer that express Prostate Specific Membrane Antigen (PSMA). ...
BPH, also known as enlarged prostate disease, is a non-cancerous condition that can make urination difficult or painful and is common in men over the age of 50. ...